GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » EV-to-FCF

CTLT (Catalent) EV-to-FCF : 162.97 (As of Jul. 23, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Catalent EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Catalent's Enterprise Value is $16,134 Mil. Catalent's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $99 Mil. Therefore, Catalent's EV-to-FCF for today is 162.97.

The historical rank and industry rank for Catalent's EV-to-FCF or its related term are showing as below:

CTLT' s EV-to-FCF Range Over the Past 10 Years
Min: -644.24   Med: 37.46   Max: 903.13
Current: 162.97

During the past 13 years, the highest EV-to-FCF of Catalent was 903.13. The lowest was -644.24. And the median was 37.46.

CTLT's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 25.5 vs CTLT: 162.97

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-23), Catalent's stock price is $63.48. Catalent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.270. Therefore, Catalent's PE Ratio (TTM) for today is At Loss.


Catalent EV-to-FCF Historical Data

The historical data trend for Catalent's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent EV-to-FCF Chart

Catalent Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -562.32 -83.33 -103.54 -38.50 -250.94

Catalent Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.27 -49.06 -122.28 -250.94 157.62

Competitive Comparison of Catalent's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Catalent's EV-to-FCF falls into.


;
;

Catalent EV-to-FCF Calculation

Catalent's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=16134.355/99
=162.97

Catalent's current Enterprise Value is $16,134 Mil.
Catalent's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalent  (NYSE:CTLT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Catalent's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=63.48/-2.270
=At Loss

Catalent's share price for today is $63.48.
Catalent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Catalent EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Catalent's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent Business Description

Traded in Other Exchanges
N/A
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
Joseph Anthony Ferraro officer: SVP, General Counsel, CCO 56 EMILY ROAD, FAR HILLS FL 07931
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lisa Evoli officer: SVP, Chief HR Officer 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Matti Masanovich officer: SVP, Chief Financial Officer COLLINS & AIKMAN CORPORATION, 250 STEPHENSON HIGHWAY, TROY MI 48083
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Jonathan Arnold officer: President, Oral Drug Delivery C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven L Fasman officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873